For the quarter ended March 2025, HudBay Minerals (HBM) reported revenue of $594.9 million, up 13.3% over the same period last year. EPS came in at $0.24, compared to $0.16 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $518.52 million, representing a surprise of +14.73%. The company delivered an EPS surprise of +140.00%, with the consensus EPS estimate being $0.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Group 1 - CVS Health briefly took the top S&P 500 year-to-date performance spot away from Palantir in early May [1] - The Health Care Services industry company, once considered to be struggling, has shown signs of recovery since bottoming around the turn of the year [1]

Core Insights - Haemonetics reported revenue of $330.6 million for the quarter ended March 2025, a decrease of 3.7% year-over-year, but exceeded the Zacks Consensus Estimate by 1.00% [1] - The company's EPS for the quarter was $1.24, up from $0.90 in the same quarter last year, representing a surprise of 1.64% over the consensus estimate of $1.22 [1] Revenue Breakdown - Plasma segment net revenues were $126.74 million, slightly below the estimated $127.03 million, reflecting an 8.6% decline year-over-year [4] - Hospital segment net revenues reached $147.86 million, surpassing the average estimate of $147.41 million, with a year-over-year increase of 14.5% [4] - Blood Center segment net revenues were $56.01 million, exceeding the estimated $53.14 million, but showed a significant decline of 20.3% compared to the previous year [4] Stock Performance - Haemonetics shares have returned +14.8% over the past month, outperforming the Zacks S&P 500 composite's +13.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Aspen Aerogels (ASPN) reported $78.72 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 16.7%. EPS of -$0.06 for the same period compares to $0.01 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $82.94 million, representing a surprise of -5.08%. The company delivered an EPS surprise of +14.29%, with the consensus EPS estimate being -$0.07.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

For the quarter ended March 2025, Gogo (GOGO) reported revenue of $230.31 million, up 120.8% over the same period last year. EPS came in at $0.18, compared to $0.16 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $214.48 million, representing a surprise of +7.38%. The company delivered an EPS surprise of +260.00%, with the consensus EPS estimate being $0.05.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Core Insights - 10x Genomics reported revenue of $154.88 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $133.25 million by 16.24% [1] - The company posted an EPS of -$0.36, an improvement from -$0.50 in the same quarter last year, with a surprise of 20.00% compared to the consensus estimate of -$0.45 [1] Revenue Breakdown - Consumables revenue reached $115.36 million, slightly below the average estimate of $115.85 million, marking a year-over-year increase of 4.6% [4] - Instruments revenue was reported at $14.82 million, significantly lower than the average estimate of $17.30 million, representing a year-over-year decline of 41.8% [4] - Chromium instruments generated $5.91 million, compared to the estimated $6.46 million [4] - Services revenue was $7.65 million, exceeding the average estimate of $6.30 million, with a year-over-year increase of 46.7% [4] - Consumables from Chromium totaled $84.11 million, surpassing the average estimate of $82.93 million [4] - Spatial consumables revenue was $31.25 million, slightly below the average estimate of $32.91 million [4] - Spatial instruments revenue was $8.90 million, compared to the estimated $10.85 million [4] Stock Performance - Over the past month, shares of 10x Genomics have declined by 4.2%, while the Zacks S&P 500 composite increased by 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Warby Parker Inc. (WRBY) reported $223.78 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 11.9%. EPS of $0.12 for the same period compares to $0.08 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $225.88 million, representing a surprise of -0.93%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.12.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- a ...

Kenvue (KVUE) reported $3.74 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.9%. EPS of $0.24 for the same period compares to $0.28 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.68 billion, representing a surprise of +1.70%. The company delivered an EPS surprise of +9.09%, with the consensus EPS estimate being $0.22.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Core Insights - Carvana reported $4.23 billion in revenue for Q1 2025, a year-over-year increase of 38.3% and an EPS of $1.51 compared to -$0.41 a year ago, exceeding Zacks Consensus Estimates for revenue and EPS [1] - The company has shown strong stock performance, with shares returning +46.8% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change, and currently holds a Zacks Rank 1 (Strong Buy) [3] Financial Performance Metrics - Retail vehicle unit sales reached 133,898, surpassing the six-analyst average estimate of 129,401 [4] - Retail vehicle sales, net, amounted to $2.98 billion, exceeding the four-analyst average estimate of $2.88 billion, representing a year-over-year change of +37% [4] - Wholesale sales and revenues were reported at $863 million, above the estimated $804.95 million, reflecting a +31.4% change year-over-year [4] - Other sales and revenues totaled $389 million, exceeding the estimated $339.14 million, with a significant year-over-year increase of +69.9% [4] Profitability Metrics - Per retail unit gross profit totaled $6,938, slightly below the estimated $6,956.18 [4] - Per retail unit gross profit for retail vehicles was $3,204, compared to the average estimate of $3,350.74 [4] - Per unit revenue for retail vehicles was $22,256, lower than the estimated $22,762.43 [4]

For the quarter ended March 2025, MKS Instruments (MKSI) reported revenue of $936 million, up 7.8% over the same period last year. EPS came in at $1.71, compared to $1.18 in the year-ago quarter.The reported revenue represents a surprise of +0.27% over the Zacks Consensus Estimate of $933.5 million. With the consensus EPS estimate being $1.42, the EPS surprise was +20.42%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...